The molecular basis of autoantibody reactivity with components of the SSA/Ro-SSB/La particle exhibited by sera of mothers of infants with severe and permanent manifestations of neonatal lupus (NLE) was investigated using immunoblotting and immunoprecipitation. The characteristics of NLE that were studied included congenital complete heart block (CCHB), second degree heart block, and hepatic fibrosis. Antibodies specific for one or more components of the SSA/Ro-SSB/La particle were found in sera from all 20 mothers of permanently affected infants. However, no antibody specific for a single peptide of this particle was common to all sera. Using tissue extracts from a human cell substrate, 80% of these sera had antibodies to one or more components of the SSA/Ro particle demonstrable by immunoblotting. The predominant antibody response in the NLE group was to the newly recognized 52-kD SSA/Ro peptide component. In contrast, antibodies to the 60-kD SSA/Ro component although present, were the least represented and not significantly increased in frequency among mothers of these infants, compared with a group of 31 mothers with autoimmune diseases such as systemic lupus erythromatosus (SLE) but who had healthy offspring. Antibodies directed to the 48-kD SSB/La antigen were demonstrated in 90% of the NLE mothers often accompanying antibodies against the 52-kD SSA/Ro component. The combination of antibodies to 48-and 52-kD structures was significantly increased in the NLE group, with an odds ratio of 35. The type of cell or tissue substrate was shown to influence detectability of antibodies. The 52-kD SSA/Ro peptide and the 48-kD SSB/La peptide were abundant in cardiac tissues from fetuses aged 18-24 wk, further supporting the possible relevance of these peptides to heart block.
Introduction
The potentially severe and permanent manifestation of neonatal lupus (NLE),' congenital complete heart block (CCHB) 1 . Abbreviations used in this paper: ARA, American Rheumatism Association; CCHB, complete congenital heart block; NLE, neonatal lupus; SS, Sjogren's Syndrome. appearing after the first trimester of pregnancy is significant both as a model for a passively acquired autoimmune disease and in terms of diagnosis and management. The mechanism ofdisease is considered to depend on the placental transport of maternal antibodies capable of initiating specific myocardial inflammation that permanently damages the conduction system ofthe developing fetal heart (1); however, the nature ofthe antigen-antibody system or systems involved in the injury of the fetal heart remains as a challenge for investigation.
The recognition that antibodies to the SSA/Ro ribonucleoprotein complex were found in as many as 85% of sera from mothers of infants with CCHB or other manifestations of passively acquired NLE such as skin or liver disease was an important advance, directing attention to this antigen as a potential candidate despite its intracellular location (2) (3) (4) (5) (6) . The possibility that the SSB/La antigen-antibody system might also be involved in the development of CCHB has been suggested (7) because of the vast predominance of antibodies reactive with the SSB/La protein found in certain patients (7, 8) , but no systematic study ofthe occurrence ofantibodies to all elements of the SSA/Ro-SSB/La particle has been performed in the NLE group.
Knowledge of the structures that bear the SSA/Ro antigens, while still incomplete, is rapidly growing. The first major antigenic component of SSA/Ro to be described was a polypeptide of 60 kD (9) . This gene has been cloned (10). A protein sequence of a 60-kD component has also been reported that differs in sequence from the 60-kD species (1 1). Its occurrence and relationship to the 60-kD species is currently unknown.
Using immunoblot techniques, another polypeptide in the human SSA/Ro complex has been identified as a 52-kD species (12) . It has not yet been cloned or chemically purified nor has its presence in other species been studied. The 52-kD protein is antigenically and structurally distinct from the 60-kD protein (12) . Both the 60-kD and the 52-kD SSA/Ro peptides are associated with four RNA species designated hYl, hY3, hY4, hY5 (9, 12) . Other evidence for multiple forms of the SSA/Ro structure have been reported and that found in fetal red blood cells apparently associates with only two RNA species (13) . Additionally there are species differences in the structure of the SSA/Ro complex, with only two RNA species, mYl and mY2, identified in the mouse (14) . The presence of the SSA/Ro antigen in fetal cardiac tissue has been reported using immunofluorescence techniques (5) , and a 60-kD SSA/ Ro polypeptide was biochemically identified (6) .
The intricacy of the SSA/Ro polypeptide-RNA complex is further complicated by its association with the 48-kD SSB/La protein forming a larger assembly (9, 15) . The SSB/La protein does not share antigenic determinants with the SSA/Ro peptides and the genes encoding them show no homology (16, 17) . The SSB/La component is complexed to a spectrum of RNAs that includes precursor forms of 5S rRNA and tRNA, certain small viral RNAs and the SSA/Ro-associated RNAs (18) . In terms of biologic function, the SSB/La protein appears to be involved in the maturation of RNA polymerase III transcripts (18) , probably in the termination of transcription (19).
This study was initiated to obtain a more precise molecular characterization of the relevant antigenic structures identified by the immune response in women with offspring with NLE, predominantly CCHB, and to determine whether these components, particularly the 52-kD SSA/Ro peptide, are expressed in fetal cardiac tissue. The specific objectives included using the resolution of gel separation methods to define the apparent molecular masses of these autoantigens to determine whether one or both of the components of the SSA/Ro particle are recognized by antibodies in the sera of NLE mothers and whether antibodies to SSB/La are prevalent.
Methods
Patients' sera. Two groups of sera were evaluated. The first group consisted ofsera obtained from 20 women having offspring with severe and permanent manifestations of NLE. 18 women (patients A-T, except C and I; see Table I ) were either pregnant with a fetus documented by echocardiogram to have CCHB or had recently given birth to a child with CCHB. One woman (patient I) gave birth to an infant with second degree heart block and another (patient C) had a child with neonatal skin disease and hepatic fibrosis in whom heart block was not documented. Ofthis group, two fulfilled a set of criteria for the diagnosis of Sjogren's Syndrome (SS) (20) Briefly, for RNA analysis, K562 cells at 0.5 X 106/ml were labeled with 25 MCi/ml [32P]orthophosphoric acid (carrier free, New England Nuclear, Boston, MA) in low phosphate DME (phosphate-free MEM [Gibco Laboratories]) at 37°C for 15 h. Cells were harvested, washed in PBS, and lysed in buffer containing 10 mM Tris pH 7.5, 10 mM KCI, 1 mM Na2 EDTA, 5 mM iodoacetamide and 0.5 mM PMSF at 106/100 !A. After the cells were swollen on ice and sheared in a Dounce homogenizer, the lysate was rendered 200 mM in NaCl. Lysates were clarified by centrifugation and supernatants used immediately for immunoprecipitation of RNA.
RNA immunoprecipitation procedures. Protein A Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ)-facilitated immunoprecipitation of labeled cellular antigen by antisera was performed as described (24) . Briefly, 10 ul of each serum was added to 100 ;lI lysate (106 cell equivalents) and the mixture incubated on ice for 10 min. 40 Ml of 50% protein A-Sepharose was then added and incubated with rotation for 45 min at 4°C. Beads were washed twice with mixed micelle buffer 150 mM NaCl, 50 mM Tris pH 7.5, 2 mM EDTA, 0.25 M sucrose, 2.5% Triton X-100 and 0.5% SDS, and three times in 150 mM NaCl, 50 mM Tris pH 7.5, 2 mM Na2 EDTA. RNA was then extracted with phenol/ chloroform, precipitated with ethanol, and run on 7% polyacrylamide-7 M urea gels. These were dried and the bands detected by autoradiography. (Tables I and II) . The reaction patterns of the sera of affected neonates were indistinguishable from those of their mothers (Table I ). In comparison, among 31 pregnant patients with SLE or Sjogren's syndrome who had offspring without evidence of NLE only 12 sera contained antibodies to the SSA/Ro particle, P < 0.01, demonstrable by immunoblotting (Table II) . 10 of these 12 non-NLE mothers (32% of the group) had antibodies to the 60-kD SSA/Ro com- (Tables I and III) .
Comparison of the immunoblots illustrated in Fig. 1 reacting with MOLT4 cell extracts to those illustrated in Fig. 2 using HeLa cell extracts revealed that the former preparation was a better source of the 60-kD antigen, thereby providing a stronger signal for its detection. This is demonstrated by the comparison of Fig. 1, lane 9, and Fig. 2 , lane 1, both studied with serum from the same affected mother, L. Of note, serum from affected mothers E and F reacted with the 52-kD Ro component and not the 60-kD on both substrates (Fig. 1, lanes  10 and 14, Fig. 2, lanes 6 and 10) . In experiments not depicted, the possibility was explored that the weaker reactivity with the 60-kD species reflected a lower titer of antibodies. Accordingly, the immunoblots were performed with antisera at a 10-fold greater concentration. The pattern of reactivity remained 1 (27) . Only 26% of sera from mothers in the unaffected group had antibodies to SSB/La (Table II) . Table III lists the patterns of antibody responses to one or more components of the SSA/Ro-SSB/La complex detected upon immunoblotting in NLE and non-NLE pregnancies. The three most common patterns in the NLE group included antibodies recognizing the 48-kD SSB/La antigen either in combination with antibodies directed to the 52-kD SSA/Ro component (35%), in combination with antibodies against both the 52-and the 60-kD Ro components (30%) or in isolation (20%) ( Table III) . The respective values in non-NLE mothers for the latter two profiles were 16 and 6%. These differences were not statistically significant. However, of particular interest, there were no patients in the non-NLE group with antibodies simultaneously to both the 52-and 48-kD components in the absence of reactivity to the 60-kD component, although this was a prevalent antibody profile seen in the 20 individuals in the NLE group (odds ratio = 35, P < 0.001, Table III Immunoblot of extracts from fetal cardiac tissue. Because the central goal of this study was to characterize the antigenantibody systems associated with the development of NLE and specifically CCHB, the relative amounts of SSA/Ro and SSB/ La antigens were determined in fetal heart tissues, ages 18-24 wk. Using immunoblot analysis, the fetal heart antigen preparations contained a preponderance of SSB/La 48-kD antigen relative to either the 60-or 52-kD SSA/Ro antigen species (Figs. 3 and 4) . The 52-kD SSA/Ro protein was seen to be present in all these fetal extracts, and gave a stronger signal relative to the 60-kD antigen in the 1 8-wk fetus. This pattern of 52-kD component predominance was also noted in a tissue extract of an 18-wk fetal liver and cord red blood cells as demonstrated by the reactivity of serum from mother P and the prototype positive control serum, which contains antibodies to both the 52-and the 60-kD components defined using MOLT4 (Fig. 3) .
Examination of the antibody specificities of 15 sera from NLE mothers using a cardiac extract of an 1 8-wk fetus reveals that all but one of the sera tested had anti-SSA/Ro profiles equivalent to those obtained with either MOLT4 or HeLa cell extracts (Table I, Fig. 4 ). The serum from individual J, which reacted with the 60-kD Ro antigen in the HeLa and MOLT4 preparations did not react with the 60-kD species in the fetal heart tissue (Fig. 4, lane 3) . In contrast, this serum was weakly reactive against the 52-kD SSA/Ro component using MOLT4 cells, unreactive with the HeLa extract, but did demonstrate weak reactivity against the 52-kD Ro antigen in the heart preparation. Each of 13 mothers with anti-La antibodies defined on MOLT4 and HeLa cell extracts reacted with the 48-kD antigen in the fetal heart. Immunoprecipitation of32P-labeled RNA. The RNA bands precipitated by sera from 13 CCHB mothers studied by this method confirmed the antibody profiles defined in the immunoblot analysis, Fig. 5 , Table I . For example the two sera, P and Q, which contained antibodies to both the 52-and 60-kD antigens and not the 48-kD antigen precipitated the expected Figure 3 . Immunoblotting analysis demonstrating the separate specificities of individuals A and P using extracts from several fetal tissues. The positive (+) control is described in Fig. 1 . In this experiment the neg- Table I . Lane 10 is probed with serum from a normal donor. Lanes 11-13 are probed with sera from three pregnant lupus patients carrying healthy fetuses (-CCHB).
RNA species hYl-hY5 associated with the SSA/Ro particle and curiously in one case immunoprecipitated an RNA species of mass similar to tRNA. The remaining 11 sera precipitated the SSB/La associated RNA species, including the 5S RNA and tRNA precursors, as well as the hYl-hY5 species, emphasizing the predominance of the anti SSB/La antigen response in these sera. Of particular interest, the only set of RNA species uniformly precipitated by all of the mothers of NLE children was the hYl-hY5 system. HLA typing. In agreement with previously published immunogenetic studies (28) , there was a high frequency of the DR3 phenotype in mothers of offspring with NLE (Table I) . Eight of nine affected mothers evaluated in this study were DR3. However, DR3 was found with all patterns of antibody response, including the presence of detectable antibodies to SSB/La. Six of these eight DR3-positive women had antibodies to the 52-kD SSA/Ro antigen. The one DR3-negative individual, L, had antibodies to the 52-kD antigen. In mothers of unaffected offspring, 12 of 25 were DR3. Of these 12, 5 had antibodies to the 52-kD antigen. In this group, there were three mothers who had antibodies to the 52-kD protein but were not DR3.
Discussion
In this study, we initiated the definition of the antibody response to molecularly characterized components of the SSA/ Ro-SSB/La system in mothers of infants with CCHB and other permanent manifestations of NLE. The central finding is that all individuals have antibodies to one or more components of the SSA/Ro-SSB/La system, identified by immunoblotting, but that no antibody to a single antigen detectable by these methods is uniformly demonstrable. As has been emphasized by other workers (2-4), antibodies to the SSA/Ro particle are commonly encountered. Here, surprisingly, antibodies to the well-characterized 60-kD SSA/Ro polypeptide, although present, were not significantly increased in frequency over that in a control group of mothers who had SLE or SS without evidence of fetal heart block. In Lanes 7 and 8 (Q and P) demonstrate the RNAs precipitated by sera containing both anti-60-kD and anti-52-kD antibodies. Lane 14 demonstrates the RNA's precipitated by a pregnant lupus patient who subsequently gave birth to a healthy offspring. Note that although this serum brings down the spectrum of RNAs associated with the SSA/Ro particle, by immunoblotting, it detects a species migrating slightly> 52 kD but clearly <60 kD. For data presentation, this control serum was coded as reacting with the 52-kD species. The designation of Y RNAs is based on the data of Hendrick et al. (32). immunoblotting, is dissociable with antibodies to the smaller SSA/Ro peptide of greater significance for this disease entity. Of note, the percentage of patients with antibodies to the 52-kD antigen encountered in the non-NLE group (29 of 31 had SLE) was similar to the recently reported frequency of 43% in a group of SLE patients (29) .
A significant point that emerged from this analysis is that antibodies to the 48-kD SSB/La antigen and its 43-kD degradation product were both found in the highest prevalence and were the antibody species most strongly associated with NLE, providing an odds ratio of 20.5. The individuals without detectable antibodies either to 52-or 60-kD SSA/Ro antigens each had very high levels of antibodies that reacted with the SSB/La polypeptides. Moreover, the combination of antibodies demonstrable to both the 48-kD SSB/La polypeptide and the 52-kD SSA/Ro polypeptide, but not to the 60-kD SSA/Ro species, was most strongly associated with the occurrence of NLE, odds ratio 35. The results of the 32P-RNA immunoprecipitated by the antibodies paralleled the specificities of the peptides identified by immunoblotting with the interesting exception ofa band with apparent mass oftRNA in serum P that does not react detectably with the 48-kD La peptide. Of interest, the hYl-5 species were found in the precipitates ofall NLE sera studied, suggesting that perhaps a polypeptide associated with these RNA species could have a special relationship to the pathogenesis of NLE.
Support for the possible importance of the particle containing the 48-kD SSB/La peptide as directly relevant to the pathogenesis of NLE came from analysis of fetal cardiac tissue that had abundant 48-kD SSB/La peptide demonstrable. In addition, the 52-kD SSA/Ro species was readily evident, although at lower levels, while still smaller quantities of the 60-kD peptide were found. A similar pattern of peptide abundance was seen in several other cell lines. Nevertheless, the detectability of certain peptides varied according to the source of the cells. Particular attention had to be directed to developing analytic electrophoretic conditions that reliably separated the 48-kD La protein and the 52-kD Ro protein. The antigen unrelatedness of these species is demonstrated in Fig. 3 using a preparation in which one serum reacts with the intact 52-kD component while another serum reacts only with the lower molecular weight SSB/La degradation components. In the course of this work we found that the detection method that used 125I-Protein A was distinctly superior to those methods using an alkaline phosphatase-based system involving antihuman Ig antibodies. In particular, fetal cardiac extracts yielded a band, tentatively identified as actin, which partially overlapped and often interfered with the detection of the 52-kD protein when rabbit or goat anti-human IgG antibodies were used (data not shown). This interference was not encountered with radiolabeled Protein A. Particular attention to the washing steps was also necessary to achieve a low overall background.
Although this study did not address the interrelationship of the 52-and 60-kD SSA/Ro polypeptides, it provides further support for their operational independence by demonstrating maternal sera with separate specificities for the 52-kD component. Additionally, earlier studies demonstrated the lack of cross-reactivity between antibodies affinity purified from each protein as well as the lack of common protease-resistant fragments in the partial proteolysis of the proteins (12) . Although evidence mounts concerning how the 52-kD SSA/Ro antigen differs from the 60-kD antigen, in their native state both of these polypeptides appear to exist as a complex with hYl-hY5 molecules. Furthermore, although none of the affected mothers had antibodies exclusively reactive against the 52-kD antigen, previous work has shown that the small RNA species precipitated by anti-52-kD antibodies are identical to that precipitated by antibodies to the 60-kD alone (12) . In the two NLE mothers with reactivity against both SSA/Ro components, the precipitated RNA species were the expected hYlhY5 associated with SSA/Ro. Of interest it is possible that the 52-kD SSA/Ro species was recognized but not identified in a report stating monospecific anti-Ro sera recognized a 50-kD protein on immunoblotting, considered to be SSB/La but which did not precipitate the expected SSB/La associated RNAs (9) . In retrospect, these sera may have identified the 52-kD SSA/Ro peptide component.
Although the central point of this study was to analyze the specificity of the autoantibodies in mothers of infants with NLE using resolving methods that permit identification of the autoantigens, at least in terms of apparent mass, the results have some relevance to the general area of testing antibodies to SSA/Ro-SSB/La by ELISA and double diffusion methods. Pending the cloning and expression of all the peptides of the SSA/Ro-SSB/La particle that will provide a definitive answer to issues of sensitivity and specificity of antibody detectability and antigen definition, each currently available method has advantages and disadvantages. In principle, for example, as a screening test, the specificity of immunoblotting can be offset by a lack of sensitivity, especially for epitopes altered by denaturation and a bias to high affinity antibodies. In contrast, the sensitivity of ELISA methods may be circumscribed by the presence of minute quantities of contaminating antigen. It was of interest to encounter several sera that reacted with purified bovine SSA/Ro by ELISA but that did not yield demonstrable 52-or 60-kD bands with the immunoblotting procedure. One interpretation of the former observation is that certain epitopes on SSA/Ro peptides might be altered by denaturation. In support of this is the finding by Ben-Chetrit et al. that 6 of 42 sera containing antibodies to SSA/Ro demonstrable in double diffusion analysis were not reactive in immunoblotting (12) . In contrast, the specificities of the NLE sera appear distinctive in that they are predominantly directed to epitopes on SSA/Ro-SSB/La peptides that resist the denaturing effect of SDS, electrophoresis, and transfer. Reciprocally, some evidence suggests that sera containing abundantly detectable antibodies to the 52-kD SSA/Ro peptide using a human antigen preparation did not react with the partially purified bovine SSA/Ro antigen preparation. With respect to the latter observation, the variations in reactivity in ELISA systems that result from speciesrelated differences in structure of the SSA/Ro particle have been the subject of detailed study (30) .
The biologic relevance of antibodies demonstrable with immunoblot techniques to the intracellular 48-, 52-, and 60-kD antigens in the pathogenesis of NLE remains unknown. Although the presence of antibodies reactive in this technique appears to be a characteristic of these patients, the antibodies are not in themselves sufficient for the development of the syndrome. Indeed, these antibodies could be only clinically useful markers of the production of antibodies to an unrelated but conformationally equivalent membrane structure. Alternatively, as previously suggested (31), translocation of a component of intracellular SSA/Ro to the cell surface may be a critical element. However, that the common feature of each NLE mother is the production of antibodies to some, and often different, elements of the SSA/Ro-SSB/La particle assembly directs attention both to the regulation of the production of these autoantibodies and to the cell biology of this particle assembly and its possible unique function during the stage of cardiac development when the fetus, but not the mother, is at risk for this syndrome.
